Τα πιστοποιητικά είναι διαθέσιμα!
A. Klinakis (GR)
Homologous Recombination and Genome Instability
Chair: A. Klinakis (GR)
09.15–09.40 Chromosome instability as a driver of human disease I. Hickson (DK)
09.40–10.05 DNA repair and replication stress W. Niedzwiedz (UK)
10.05–10.30 Understanding the role of homologous recombination proteins
in suppressing DNA replication stress V. Costanzo (IT)
Speakers:
- Garinis G.Professor of Genetics , Department of Biology, University of Crete, Affiliated Group leader at IMBB-FORTH, Greece
- Dangaj D.PhD, Privat Docent (Lecturer), Group Leader, Laboratory Tumor Microenvironment and Biomarker Discovery, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Switzerland
- Chapman R.MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK
- Niedzwiedz W.Professor, PhD, Genome Instability and Cancer Team, The Institute of Cancer Research, London, UK
Speakers:
- Antonarakis S.Professor Emeritus, University of Geneva Medical School, Switzerland / MediGenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland
Chair: G. Garinis (GR)
DNA damage, cancer and aging and the unexpected impact of nutrition
and gene length J. Hoeijmakers (NL)
Chair: A. Klinakis (GR)
11.30-11.55 DNA damage and Innate Immune signalling during ageing G. Garinis (GR)
11.55-12.20 Staggered CRISPR/Cas9-induced DSBs for precise, predictable
and personalized genome editing V. Roukos (GR)
12.20-12.45 The ESC paradox: Hyper recombination does not shield embryonic
stem cells from PARP inhibitor-induce cytotoxicity R. Carreira (UK)
Speakers:
- Malapelle U.Associate Professor in School of Medicine, Chair of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples, Naples, Italy
- Guerini Rocco E.Associate Professor of Pathology, Department of Oncology and Hemato-Oncology, University of Milan, and Chair of Molecular Pathology Unit, Division of Pathology, European Institute of Oncology, IRCCS, Milano, Italy
- Christoforou E.Senior Scientist, AstraZeneca, Early Oncology R&D, Translational Medicine Epigenomics, UK
- Christopoulou G.MSc, PhD, Lab Director, Head of Genetics & Genomics Dpt, Genotypos S.A.
- Papadopoulou Eir.PhD, International Laboratory Director, Genekor Medical S.A., Greece
Speakers:
- Soutoglou E.Professor of Genome Stability, Genome Damage and Stability Centre, Sussex University, School of Life Sciences, University of Sussex, Brighton, UK
Chair: A. Klinakis (GR), P. Constantoulakis (GR)
• A single laboratory’s experience on over 5.000 HRD tests.
Actual results and pitfalls M. Roussou (GR)
• Clinical Utility of HRR Genetic Testing in PARP Inhibitor Treatment:
Real-World Evidence A. Meintani (GR)
• FLEXing the Genome: From Loss-of-Function Mutation Discovery to
a WGS-Based Alternative Lengthening of Telomeres (ALT) Classifier A. Mohan (UK)
Chair: P. Constantoulakis (GR), G. Nasioulas (GR)
16.00-16.25 Comparing two NGS approaches for HRD estimation on
clinical samples G. Christopoulou(GR)
16.25-16.50 Implementation and Validation of Homologous
Recombination Deficiency Detection in a Comprehensive
Genomic Profiling Assay E. Papadopoulou (GR)
16.50-17.15 Persistence of BRCA1 methylation following neoadjuvant
chemotherapy in breast cancer S. Pettitt (UK)
17.15-17.40 Determination of HRD status by liquid biopsy in high-grade
serous ovarian cancer: insights from the BOVARY-Pilot study A. Witz (FR)
Speakers:
- Stewart G.Professor, Department of Cancer and Genomic Sciences, University of Birmingham, UK
- Pasero P.Institute of Human Genetics, CNRS and University of Montpellier, France
- Halazonetis T.Professor, Dept of Molecular and Cellular Biology, University of Geneva, Switzerland
- Rampias T.PhD, Investigator - Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece
- Klinakis A.PhD, Investigator, Biomedical Research Foundation of the Academy of Athens, Greece
Chairs: S. Linardopoulos (UK), F. Papageorgiou (GR)
17.30-17.55 Genomic instability and clinical utility beyond HRR genes A. Svarna (GR)
17.55-18.20 Genomic instability in Non-Small Cell Lung Cancer V. Anastasopoulou (GR)
18.20-18.45 Combinatorial treatment in the era of PARPi M. Liontos (GR)
18.45-19.10 Updated the treatment status in ovarian cancer R. Zakopoulou (GR)
Chair: W. Niedzwiedz (UK)
09.00-09.25 Epigenetics and DNA damage response A. Klinakis (GR)
09.25-09.50 Chromatin organisation, epigenome maintenance and
DNA replication Cr. Cardoso (DE)
09.50-10.15 Principles of cGAS activation by DNA damage and
chromosomal instability revealed by a versatile
cGAMP reporter Ch. Zierhut (UK)
10.15-10.40 Regulation of Homologous Recombination - Role of
RAD51 Filament Assembly and Disassembly L. Krejci (CZ)
10.40-11.00 Epigenetics of bladder cancer evolution D. Karagiannis (GR)
Speakers:
- Anastasopoulou V.Postdoctoral Researcher, Hellenic Oncology Research Group, Athens, Greece
- Liontos M.Medical Oncologist, Assistant Professor Dept of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
- Fountzila E.Medical Oncologist, Clinical Associate Professor, European University Cyprus, St Lukes Hospital, Thessaloniki, Greece
- Zakopoulou R.MD, PhD, Medical Oncologist, Locum Consultant, General Anticancer Hospital “Agioi Anargyroi”, Athens, Greece
Speakers:
- Sammut S.J.MD, PhD, Group Leader, Cancer Dynamics Lab, Consultant Medical Oncologist, The Royal Marsden Hospital, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Chester Beatty Laboratories, London, UK
- Gounaris I.MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA
- Loizou J.Group Leader Divisions of Cancer Therapeutics and Breast Cancer Research | Deputy Director Centre for Target Validation, The Institute of Cancer Research, UK
Chair: D. Dangaj (CH)
11.30-11.55 Therapy-Induced Remodeling of the Ovarian Cancer
Microenvironment: Linking Homologous Recombination
Deficiency to Immune Vulnerability D. Dangaj (CH)
11.55-12.20 Precision meducine in BRCA mutated women’s cancer I. Labidi-Galy (CH)
12.20-12.45 Clinical and Genomic Heterogeneity DNA repair in Ovarian Cancer:
Unveiling the Role of the Spatial Tumor Microenvironment A. Farkkila (FI)
12.45-13.10 TCF1: more than a T cell factor 1, emerging biomarker with
clinical benefit in solid tumors I. Pateras (GR)
Speakers:
- Tan T.Senior Consultant Medical Oncologist, National Cancer Centre Singapore
- Gounaris I.MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA
- Albertella M.D Phil, Senior Director, Bioscience, AstraZeneca Oncology R&D, Cambridge, UK
- Linardopoulos S.Director, Translational Science, Oncology AstraZeneca, Cambridge, UK
Chair: M. Liontos (GR), S. Linardopoulos (UK)
• Elucidating the functional role of the DREAM complex
in mammals Aik. Zacharopoulou (GR)
• MLL3 deficiency impairs melanoma growth and metastasis K. Karakostas (GR)
• Clinical outcome of patients with early and metastatic NSCLC harboring
high Genomic Scarring Score (GSS) N. Asimakopoulou(GR)
Chairs: Α. Klinakis (GR), W. Niedzwiedz (UK)
15.20-15.45 Targeting DNA polymerase theta in cancer treatment J.V. Forment (UK)
15.45-16.10 Synthetic lethal interactions for the DNA damage response J. Loizou (UK)
16.10-16.35 Combination of the PARP1-selective inhibitor saruparib with
androgen receptor pathway inhibition provides combination
benefit in preclinical models of prostate cancer with or without
homologous recombination repair deficiency M. Albertella (UK)
16.35-17.00 Saruparib+androgen redeptor pathway inhibitor (ARPI) +
androgen deprivation therapy (ADT) in patients with
metastatic hormone-sensitive prostate cancer (mHSPC):
The Phase 1/2 PETANHA trial S. Linardopoulos (UK)
Speakers:
- Burghel G.Consultant Clinical Scientist, North West Genomic Laboratory Hub) / Honorary Senior Lecturer, University of Manchester, UK
- Gagos S.Principal Investigator Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece
- Rampias T.PhD, Investigator - Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece
